Blog
RSS FeedPosted by Michael Wonder on 09 Aug 2024
Novo Nordisk upset as Dutch agency advises against insurance cover for Wegovy
17 July 2024 - Danish drug maker Novo Nordisk said on Wednesday it was disappointed with the recommendation to the ...
Posted by Michael Wonder on 10 Jul 2024
Pharma company lawsuit forces Dutch health agency to reassess cancer drug
9 July 2024 - The Dutch healthcare procurement agency has said it will reassess the breast cancer drug abemaciclib after ...
Posted by Michael Wonder on 05 Mar 2023
Medicine and medical device pricing and reimbursement in Netherlands
2 March 2023 - Since the Netherlands is a Member State of the European Union, it has implemented the European ...
Posted by Michael Wonder on 08 Mar 2022
Key considerations in the health technology assessment of advanced therapy medicinal products in Scotland, The Netherlands and England
8 March 2022 - Advanced therapy medicinal products are highly innovative therapies. Their costs and uncertain value claims have raised concerns ...
Posted by Michael Wonder on 13 Nov 2021
Dutch health insurance: what changes in 2022?
11 November 2021 - The Dutch healthcare institute Zorginstituut Nederland is going to increase its monitoring of treatment to better ...
Posted by Michael Wonder on 07 May 2021
World’s most expensive drug may not be covered by Dutch insurance
7 May 2021 - A drug to treat a rare muscle disease which affects some 20 children in the Netherlands ...
Posted by Michael Wonder on 05 Feb 2020
Five pillars for societal perspective
31 January 2020 - In economic evaluation, the healthcare perspective has gradually given way to use of the societal perspective, as ...
Posted by Michael Wonder on 15 Jul 2019
Implementation of “coverage with evidence development” drug approval strategies found lacking
15 July 2019 - Lessons from early deployments in The Netherlands. ...
Posted by Michael Wonder on 23 Apr 2019
Beneluxa: what are the prospects for collective bargaining on pharmaceutical prices given diverse health technology assessment processes?
23 April 2019 - The Beneluxa collaboration is an initiative aimed at securing sustainable access to new medicines. ...
Posted by Michael Wonder on 12 Apr 2019
Addressing health system values in health technology assessment: the use of evidence-informed deliberative processes
8 April 2019 - Health technology assessment is increasingly used around the globe to inform resource allocation decisions. Furthermore, the importance ...
Posted by Michael Wonder on 09 Apr 2019
Conditional financing of drugs in the Netherlands: past, present, and future—results from stakeholder interviews
8 April 2019 - It is long known that managed entry agreements may offer decision makers valuable policy options to ...
Posted by Michael Wonder on 05 Mar 2019
Determining the comparative value of pharmaceutical risk-sharing policies in non–small cell lung cancer using real-world data
2 March 2019 - Risk-sharing arrangements can be used to mitigate uncertainty about the value of a drug by sharing the ...
Posted by Michael Wonder on 21 Mar 2018
Using real world data in health technology assessment (HTA) practice: a comparative study of five HTA agencies
21 March 2018 - This study examines whether real world data is incorporated in health technology assessment (HTA) of melanoma drugs ...